<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36947">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625545</url>
  </required_header>
  <id_info>
    <org_study_id>CP00001</org_study_id>
    <nct_id>NCT02625545</nct_id>
  </id_info>
  <brief_title>Study of Median Lobe Prostatic UroLift Procedure</brief_title>
  <acronym>MedLift</acronym>
  <official_title>Study of Median Lobe Prostatic UroLift Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeoTract, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeoTract, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of using UroLift in
      subjects with a prostatic median lobe enlargement due to BPH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives: Evaluate the safety and effectiveness of the UroLiftÂ® System when used in
      symptomatic benign prostatic hyperplasia (BPH) subjects with an enlarged median lobe.

      Study Design: Prospective, multicenter, non-blinded, single arm (non-randomized) study.

      Sample Size: A total of no more than 40 subjects will be enrolled. Subject Population: Males
      age of 50 years or older diagnosed with lower urinary tract symptoms (LUTS) with enlarged
      median lobe.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IPSS Improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Mean Improvement of International Prostatic Symptom Score (IPSS) over baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>UroLift System procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible,enrolled subjects will undergo a UroLift procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UroLift System procedure</intervention_name>
    <description>Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
    <arm_group_label>UroLift System procedure</arm_group_label>
    <other_name>Prostatic UroLift (PUL)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enlarged median lobe (ML) contributing to obstruction of the prostate

          -  BPH

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan B. Rukstalis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 12, 2017</lastchanged_date>
  <firstreceived_date>December 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
